Baker Finn Recruitment’s Post

Great news for Abbott! Medical device company Abbott has opened a new manufacturing facility in Kilkenny which is is set to create more than 800 jobs. The Kilkenny facility is part of a €440 million investment in Ireland, which also includes a major expansion at the company’s Donegal site, adding another 200 jobs. https://lnkd.in/e55ndDYW

Exciting news for Abbott! Medical device company Abbott has opened a new manufacturing facility in Kilkenny which is is set to create more than 800 jobs. The Kilkenny facility is part of a €440 million investment in Ireland, which also includes a major expansion at the company’s Donegal site, adding another 200 jobs. Spanning 30,000 square meters, the Kilkenny site will become the world’s largest production hub for Abbott’s FreeStyle Libre sensors. Read more here: https://lnkd.in/eSp8dgmz

Recent Investment News in the #AutoretractableSafetySyringe Market: BD: BD has recently announced a $150 million investment in its auto-retractable safety syringe production capabilities to enhance safety and efficiency in medical settings. BD Medtronic: Medtronic's $120 million investment focuses on advancing its safety syringe technology to meet the growing demand for safer needle disposal. Medtronic Retractable Technologies: Retractable Technologies has secured $85 million in funding to expand its auto-retractable syringe production line and accelerate product development. Retractable Technologies, Inc Globe Medical Tech: Globe Medical Tech's recent $60 million investment aims to boost its R&D efforts and bring innovative auto-retractable safety syringes to market. Globe Medical Tech. Inc. Revolutions Medical: Revolutions Medical has attracted $45 million in funding for its new auto-retractable syringe product line, focusing on improving user safety and reducing needlestick injuries. Revolutions Medical DMC Medical: DMC Medical's latest $30 million investment will be directed towards scaling up its auto-retractable syringe manufacturing and expanding its market reach. DMC MEDICAL LIMITED Q Stat: Q Stat has raised $25 million to enhance its auto-retractable safety syringe technology and increase its production capacity. Q-STATE BIOSCIENCES, INC. Medicina: Medicina's recent $20 million funding is set to support its new auto-retractable syringe development projects and bolster its market presence. Medicina pharmacy Haiou Medical: Haiou Medical has secured $15 million in investment to innovate and expand its auto-retractable syringe product offerings. Haiou Medical Mediprim: Mediprim is investing $10 million to improve its auto-retractable safety syringe technology and enhance its production processes. Mediprim Read Report @ https://lnkd.in/gYbDDwc5 #HealthcareInnovation #MedicalDevices #SafetySyringes #InvestmentNews #HealthcareTrends #NeedlestickPrevention #MedicalTechnology #SyringeSafety #HealthcareFunding #AutoRetractableSyringe #MarketResearch #HealthcareInvestments #MedicalManufacturing #SafetyFirst #SyringeTechnology #MedicalResearch #HealthcareIndustry #SyringeInnovation #InvestmentUpdate #MedicalSafety #AutoRetractableSafetySyringe #BD #Medtronic #RetractableTechnologies #GlobeMedicalTech #RevolutionsMedical #DMCMedical #QStat #Medicina #HaiouMedical #Mediprim

With several countries in Asia experiencing a greying population, health supplements are an important contributor in staying healthy. The need for tools to assist the elderly is also booming. The region hosts some of the best private hospitals in the world. To sum up, the focus on the industry is growing and likewise are the opportunities. Asian Insiders #marketentry

📰 #medtechnews Ireland’s largest indigenous medical technology manufacturer, Aerogen, is to create a further 725 jobs in Galway and Shannon as part of an investment program. Great news for the local regional 👏

DoP to launch 🚀 scheme for common facilities📋 in state-supported medical device parks: DoP Secretary📢. In a significant development, the Department of Pharmaceuticals (DoP) is planning to introduce a new scheme aimed at providing common facilities for medical device parks or clusters that have been exclusively established with the financial support of respective state governments, according to Dr. Arunish Chawla, DoP secretary. This initiative coincides with the Government of Gujarat's recent allocation of Rs. 250 crores for a state-of-the-art medical device park at Nagalpar, near Rajkot. Spread across 336 acres, this park is distinguished as India’s first medical device park funded solely by a state budget, without relying on the central government's financial grant of Rs. 250 crores. The park is expected to commence operations by the end of 2025. Conceived as a commercially and economically viable project, the Nagalpar medical device park is projected to attract an investment of USD 100-150 million over the next three years. "The park is estimated to host around 400 medical device companies. The land has been allocated, and the first phase of construction has begun. Nagalpar, being an engineering hub, offers a strategic location for the park, promising good returns on investment. It will facilitate R&D, testing, manufacturing, training, and incubation for medical device companies," stated Dr H G Koshia, commissioner of the Gujarat Food and Drug Control Administration (FDCA). The Gujarat Industrial Development Corporation (GIDC) has started the process of setting up the medical device park at Nagalpar to boost medical device manufacturing in the state. To reduce import dependence and encourage domestic manufacturing of drugs and medical devices, the Indian government has implemented various measures. Under the “Promotion of Medical Devices Parks” scheme, financial assistance of Rs. 100 crore each has been approved for Uttar Pradesh, Tamil Nadu, Madhya Pradesh, and Himachal Pradesh to establish common facilities in their medical device parks. The production linked incentive (PLI) scheme, with a financial outlay of Rs. 3,420 crores, aims to boost domestic manufacturing of medical devices. Running from FY 2020-21 to FY 2027-28, this scheme offers financial incentives to selected companies at the rate of 5 per cent of incremental sales of medical devices made in India, covering four target segments, for a period of five years. Innovate Research #clinicalresearch #fmcg #innovateresearch #DoP #facilities #medicalwriting #datamanagement #regulatoryservices #Medicaldevice #projectmanagement #clinicaloperations #sitemanagement #biostatistics #biospecimen #studyfeasibility #research #cro #biospecimen #pharmaceuticals #drugsafety #drugdevelopment #clinicaltrials

Galway medical tech company Aerogen to create 725 jobs! 💼 Good news for Galway and the Medical Device industry in #Ireland with the news Aerogen are expanding operations. #IrelandJobs #MedicalDevice #Medtech #ForceRecruitment #Aerogen https://lnkd.in/ey7Z2Byk

𝐌𝐨𝐧𝐝𝐚𝐲 𝐏𝐞𝐫𝐬𝐩𝐞𝐜𝐭𝐢𝐯𝐞 The Indian government is set to introduce a new and unique pricing model for medical devices companies operating in the country. This upcoming change in pricing strategy aims to transform the medical devices industry by making it more innovative and competitive. A recent government report highlighted the need for a unique pricing structure for medical devices in India. The report emphasized that the current pricing approaches used by companies are not optimal for fostering growth and innovation in the sector. The report underscored the importance of pricing in boosting the Indian medical devices industry and making it more attractive for investment. It suggested that a revamped pricing model could help the industry reach its full potential and become a global leader. While the exact details of the new pricing model have not been disclosed yet, it is expected to be significantly different from the current pricing strategies used by medical device companies. The new model will impact how medical devices are priced and sold in the Indian market. It is designed to bring about positive changes in the industry and make it more dynamic and innovative. The primary goal of the unique pricing model is to foster innovation and growth in the medical devices sector in India. By introducing a new pricing structure, the government aims to make the industry more competitive and attractive for investment. The new pricing model is also expected to benefit consumers by making medical devices more affordable and accessible. This could lead to improved healthcare outcomes and better access to advanced medical technologies for the population. Essentially, the upcoming unique pricing model for medical device companies in India represents a significant shift in the industry's pricing strategies. While the exact details are yet to be revealed, the new model is expected to drive innovation, boost competitiveness, and improve access to medical devices in the country. https://lnkd.in/gdfJNsv2  #medicaldevices #regulations #pricing #strategy #pharmaceuticals #insights #healthcare

𝗔 𝐔𝐥𝐭𝐢𝐦𝐚𝐭𝐞 𝐆𝐮𝐢𝐝𝐞 𝐭𝐨 𝐄𝐦𝐩𝐭𝐲 𝐈𝐕 𝐁𝐚𝐠𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 [𝐏𝐃𝐅] 𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/d9XXakEJ The Empty IV Bags Market size was valued at USD 4.44 Billion in 2023 and is expected to reach USD 8.86 Billion by 2032 and grow at a CAGR of 7.31% over the forecast period 2024-2032. The increasing prevalence of chronic diseases, rising demand for intravenous therapy, and the growing geriatric population are some of the key factors driving the growth of the empty IV bags market. Additionally, advancements in healthcare infrastructure and technology, as well as the expanding pharmaceutical industry, are expected to further propel market growth. Moreover, the shift towards home healthcare services and the rising number of surgical procedures being performed globally are also contributing to the increasing demand for empty IV bags. The market is also benefiting from the growing awareness about the importance of sterile medical equipment and supplies in preventing infections and ensuring patient safety. As healthcare systems continue to evolve and focus on providing efficient and cost-effective treatment options, the demand for empty IV bags is expected to remain strong. Manufacturers are likely to invest in research and development activities to introduce innovative products that cater to specific patient needs and improve overall treatment outcomes. Top Players Baxter International Inc. Fresenius Kabi B. Braun Group  ICU Medical  Smiths Medical  Hospira MEDIPPEX : SIPPEX Medical bags Technoflex Haemotronic AMT RENOLIT Healthcare Solutions West Pharmaceutical Services  Kraton Corporation  Huaren Pharmaceutial Co., Ltd Sanxin Medtec PolyCine GmbH  Terumo Medical Corporation Medline Industries, LP ANGIPLAST PVT. LTD. (INDIA) GEM Plastics Qosina #EmptyIVBags #IVBagMarket #HealthcareSupplies #MedicalDevices #IVTherapy #PatientCare #HospitalSupplies #HealthcareInnovation #FluidManagement #MedicalTechnology #HealthTech #IVSolutions #CriticalCareSupplies #HealthcareMarket #PharmaceuticalPackaging #InfusionTherapy #MedicalEquipment #PatientSafety #HealthcareProducts #IVBagManufacturing

Hong Kong has plans to accelerate the launch of new drugs and medical devices into the market, in this discussion of the next evolution of #medicaltourism for #HongKong from Krish Sundaresan. This is certainly a much elevated, and ambitious, view from the discussion we had a decade ago, focused on mainland Chinese patients accessing innovative pharmaceuticals. Can Hong Kong be made into a “Health & Medical Innovation Hub,” as its chief executive proclaimed? https://lnkd.in/ggRKXYBC